UroGen Pharma Ltd. Ordinary Shares URGN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T18:53:58.060Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T18:53:51.011498475Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-13T18:53:57.284513+00:00
UroGen Pharma Ltd. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 32.20 | 201.3% | 29.4% | 22.97 | 135.3% | 13.4% |
| 30Δ | 31.57 | 221.4% | 28.4% | 23.67 | 130.9% | 11.4% |
| 35Δ | 28.96 | 173.5% | 18.1% | |||
| 40Δ | ||||||
| 45Δ | ||||||
| 50Δ | ||||||
| 55Δ | 25.57 | 174.4% | 9.6% | |||
| 60Δ | 24.82 | 188.4% | 8.8% | |||
| 65Δ | 23.98 | 188.6% | 7.2% | |||
| 70Δ | 23.25 | 176.2% | 5.4% | |||
| 75Δ | 22.49 | 168.9% | 4.0% | 28.49 | 101.8% | 1.9% |
| 80Δ | 21.35 | 183.1% | 3.3% | 29.03 | 98.7% | 1.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 32.20
- IV
- 201.3%
- B/E move
- 29.4%
- Pseudo strike
- 22.97
- IV
- 135.3%
- B/E move
- 13.4%
30Δ
- Pseudo strike
- 31.57
- IV
- 221.4%
- B/E move
- 28.4%
- Pseudo strike
- 23.67
- IV
- 130.9%
- B/E move
- 11.4%
35Δ
- Pseudo strike
- 28.96
- IV
- 173.5%
- B/E move
- 18.1%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 25.57
- IV
- 174.4%
- B/E move
- 9.6%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 24.82
- IV
- 188.4%
- B/E move
- 8.8%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 23.98
- IV
- 188.6%
- B/E move
- 7.2%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 23.25
- IV
- 176.2%
- B/E move
- 5.4%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 22.49
- IV
- 168.9%
- B/E move
- 4.0%
- Pseudo strike
- 28.49
- IV
- 101.8%
- B/E move
- 1.9%
80Δ
- Pseudo strike
- 21.35
- IV
- 183.1%
- B/E move
- 3.3%
- Pseudo strike
- 29.03
- IV
- 98.7%
- B/E move
- 1.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 65.68% | |
| 60.94% | |
| 62.95% | |
| 65.73% | |
| 62.38% | |
| 63.26% | |
| 63.50% | |
| 71.58% | |
| 71.52% | |
| 79.13% |
Biotechnology
VANI
Vivani Medical Inc. (VANI) is a pioneering biotechnology firm focused on revolutionizing chronic disease management through its cutting-edge drug delivery systems. The company…
More →VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care…
More →VERA
Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases in the United…
More →VERU
Veru Inc., an oncology biopharmaceutical company, focuses on the development of drugs for the treatment of cancers. The company is headquartered in Miami, Florida.
More →VIR
Description unavailable
More →VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered…
More →